

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Boill Healthcare Holdings Limited

保集健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1246)

ANNOUNCEMENT PURSUANT TO RULES 13.51B(2) AND 13.51(2)(h) OF THE LISTING RULES

This announcement is made by Boill Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51B(2) and 13.51(2)(h) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company was informed by Mr. Chui Kwong Kau (“**Mr. Chui**”), a non-executive Director, that he has been publicly criticised by the Stock Exchange on 11 April 2022 that he breached his duties of skill, care and diligence under Rule 3.08(f) and his Declaration and Undertaking with regard to Directors given to the Stock Exchange in the form set out Appendix 5B to the Listing Rules (the “**Undertaking**”) to comply with the Listing Rules to the best of his ability and to use his best endeavours to procure the compliance with the Listing Rules by Hsin Chong Group Holdings Limited (“**HCGH**”) (previous Stock Code: 404, whose listing of shares on the Stock Exchange was cancelled with effect from 31 December 2019) during his tenure of office as non-executive Director of HCGH (the “**Incident**”). As a result, Mr. Chui was requested to attend 20 hours of training on regulatory and legal topics including Listing Rules compliance (the “**Training**”). For details of the Incident, please refer to the regulatory announcement issued by the Stock Exchange on the website of the Stock Exchange on 11 April 2022 (https://www.hkex.com.hk/News/Regulatory-Announcements/2022/220411news?sc_lang=en) (the “**Regulatory Announcement**”).

Mr. Chui is a non-executive Director. He had resigned as a non-executive director of HCGH on 29 March 2019 and had already finished the Training before the date of this announcement. The Board has carefully assessed the Incident and Mr. Chui’s experience and contribution to the Company. In view of that (i) there is no evidence that the Incident involve any act of dishonesty, fraud or suggested any issue of integrity on the part of Mr. Chui which would affect Mr. Chui’s suitability as a director of the Company; and (ii) based on the information available to the Board as at the date of

this announcement, the Incident did not relate to the affairs of the Group, the Board considers that the Incident does not affect Mr. Chui's suitability as a non-executive Director and the Incident is not expected to have any material adverse impact on the business and/or operation of the Group,.

Mr. Chui has confirmed to the Company that save as disclosed in this announcement and the Regulatory Announcement, there is no other information relating to him that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and he is not aware of any other matters that need to be brought to the attention of the shareholders of the Company.

By Order of the Board
Boill Healthcare Holdings Limited
Dai Dong Xing
Executive Director and Chairman

Hong Kong, 19 April 2022

As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Dai Dong Xing and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung, Billy, Mr. Xu Liang Wei and Mr. Wang Zhe.

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.